Dallas, TX -- (SBWIRE) -- 09/20/2010 -- ReportsandReports announce The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses Market Research Report in its Store.

Browse complete Report at: http://www.reportsandreports.com/market-reports/the-top-10-pharmaceutical-companies-in-india-growth-strategies-/
Report Description:

The leading players in the Indian pharmaceutical market comprise both India-based and MNCs. This report provides an insight to the current state of Indian pharmaceutical industry as well as the evolving trends. This report analyzes the Indian pharmaceutical industry in light of market size, key drivers and resistors, trends and competitive positioning in the global market. It also analyzes the competitive landscape of the industry based on financial and operational (field force strength, R&D spend, exposure to chronic therapeutic areas and the US pharmaceutical market) parameters.

This report also compares and analyzes the competitive positioning of Indian pharmaceutical market in the context of global pharmaceutical market. The report also includes profiles of the top ten companies in the industry and also involves a brief summary of top 11 to 20 players.

The top 10 companies in the Indian pharmaceutical industry were assessed on following parameters:
• market share in the Indian pharmaceutical market;

• marketed products and therapeutic focus;

• growth strategies and major acquisitions and divestments in this market;

• key partnerships and alliances formed by these companies;

• business-related strengths and weaknesses of these companies, and insights into the opportunities and threats facing them.
Key findings

The Indian pharmaceutical market was valued at $7,743m in 2008, an increase of 4.0% over 2007. Business Insights anticipates that Indian pharmaceutical market will grow at a faster pace than the global pharmaceutical market, approximately at a CAGR of 13.2% during 2009–14 to reach a total value of $15,490m in 2014.

India has emerged as a key destination for global pharmaceutical companies due to its high growth prospects led by ageing population, changing disease profile, and improving patent regime and socio-economic conditions.

The Indian pharmaceutical market is highly competitive and fragmented with the top 10 players accounting for 36.1% of the total R&H sales in 2008.

India started to comply with World Trade Organization’s Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) agreement and recognized product patents with the amendment of the Indian Patent Act in January 2005. Indian companies plan to capitalize on Japanese government initiatives to promote generic drugs to reduce healthcare costs.

Use this report to
• Learn from the strategies of the Indian pharmaceutical companies to target future growth markets effectively, avoid their mistakes, replicate their successes and learn of the threats they face.

• Benchmark your performance against the leading Indian pharmaceutical companies using market share data by company and comprehending their strategies.

• Understand the major issues affecting the Indian pharmaceutical market.

• Predict the key growth areas in the Indian pharmaceuticals market arising from the change in the lifestyle of consumers and strengthening of the IPR regime in India.

• Save time, money and resources on analyzing the performance of the key Indian pharmaceutical companies using this report.
Key issues

Inadequacies in the new patent regime: Provisions related to Sec 3(d) of the Patent (Amendment) Act 2005 prevent ever-greening of drug patents as it does not allow patenting new uses of an existing drug. In addition, compulsory licensing allows Indian players to continue manufacturing generics of patented products for export to underdeveloped countries.

Lack of infrastructure: Problems related to frequent power cuts and lack of proper transport infrastructure will slowdown the growth of the industry.

Limited funds: Limited funding from FIs, venture capitalists and the government may slowdown the development of biotechnology industry in India.

Regulatory hurdles: Increasing due diligence and compliance with standards leads to cost overrunning and delay in new product launches.

Intense competition: Strong pricing competition among local manufacturers leads to low margins and limited capital to support R&D. Competition will further intensify from big generic players participating in the Indian market to leverage the cost advantage and large resource pool.

Discover
• What was the market size of the Indian pharmaceutical market in 2008?
• What will be the market size of the Indian pharmaceutical market during 2009-14?
• What are the trends in the Indian pharmaceutical market?
• Who are the top 20 players in the market?
• What is the market share of each of the top 10 companies?
• What are the growth strategies of the top 10 companies?
• What are the strengths of the top 10 players in the Indian pharmaceutical market?
• What are the growth opportunities for the global top 10 Indian pharmaceutical companies?
• What is the most contentious issue facing the Indian pharmaceutical market?

Table of Contents
• The Top 10 Pharmaceutical Companies in India Executive summary 12
Industry overview 12
• Cipla 13
• Ranbaxy 13
• GSK (India) 14
• Piramal Healthcare 14
• Zydus Cadila 15
• Sun Pharma 15
• Lupin Laboratories (Lupin) 16
• Alkem 16
• Sanofi-Aventis (India) 17
• Mankind Pharma (Mankind) 17

Chapter 1 Introduction 20
• What is this report about? 20
• Methodology 20

Chapter 2 Industry overview 24
• Summary 24
• Introduction 25
• Market dynamics 25
• Indian pharmaceutical market: size and growth 25
• Key market drivers and resistors 26
• India’s adoption of product patent regime 27
• Evolution of biopharmaceuticals in India 28
• Competitive positioning of India in global pharmaceutical market 30
• Competitive landscape 32
• Competitive positioning of the top 10 companies 32
• Exposure to US generics market 35
• Comparative analysis of the top 10 companies 36
• Trends 37
• Increasing participation of innovator companies in Indian pharmaceutical space 37
• Pharmaceutical companies making inroads into rural India 38
• Shifting focus towards Japanese generics market 39
• Growing prevalence of lifestyle diseases 40
• Expanding alliances in biopharmaceuticals 41

Chapter 3 Cipla 46
• Summary 46
• Company overview 47
• Marketed products 47
• Therapeutic focus 49
• Research and development 49
• Growth strategies 50
• Expanding in international markets through alliances and partnerships 50
• Expanding capabilities 50
• Growing in the US generics market 51
• Acquisitions and divestments 51
• SWOT analysis 52

Chapter 4 Ranbaxy 54
• Summary 54
• Company overview 55
• Marketed products 56
• Therapeutic focus 56
• Research and development 57
• Growth strategies 58
• Rebuilding business in the US market 58
• Shifting focus towards complex products in the US 58
• Monetizing the FTF opportunities in the US 58
• Improving penetration in emerging markets 59
• Strengthening management involvement in Ranbaxy 59
• Acquisitions and divestments 60
• SWOT analysis 61

Chapter 5 GSK (India) 64
• Summary 64
• Company overview 65
• Marketed products 66
• Therapeutic focus 66
• Research and development 67
• Growth strategies 68
•Augmenting product portfolio in India 68
• Leveraging its parent company’s product portfolio 68
• In-licensing products 69
• Expanding rural presence and hospital sales 69
• Acquisitions and divestments 70
• SWOT analysis 71

Chapter 6 Piramal Healthcare 74
• Summary 74
• Company overview 75
• Marketed products 75
• Therapeutic focus 77
• Research and development 77
• Growth strategies 78
• Capitalize on contract manufacturing opportunities 78
• Growing business through alliances and partnerships 78
• Acquisitions and divestments 79
• SWOT analysis 81

Chapter 7 Zydus Cadila 84
• Summary 84
• Company overview 85
• Marketed products 86
• Therapeutic focus 86
• Research and development 87
• Growth strategies 88
• Alliances fostering growth in international generics markets 88
•Sustaining revenue growth in Indian formulation business 89
• v
• Acquisitions and divestments 90
• SWOT analysis 91

Chapter 8 Sun Pharma 94
• Summary 94
• Company overview 95
• Marketed products 95
• Therapeutic focus 97
• Research and development 97
• Growth strategies 98
• Enhancing presence in the US market 98
• Focusing on niche segments in developing markets 98
• Plugging gaps in its business through investments 99
• Acquisitions and divestments 99
• SWOT analysis 100

Chapter 9 Lupin 102
• Summary 102
• Company overview 103
• Marketed products 103
• Therapeutic focus 104
• Research and development 104
• Growth strategies 105
• Expanding in European markets 105
• Foray into biosimilars market 105
• Sustaining growth in the US generics market 106
• Shifting focus to chronic and specialized products in India 106
• Acquisitions and divestments 106
• SWOT analysis 108

Chapter 10 Alkem 110
• Summary 110
• Company overview 111
• Marketed products 111
• Therapeutic focus 112
• Research and development 112
• Growth strategies 113
• Expanding presence in nutraceuticals business 113
• Expansion in international markets 113
• Acquisitions and divestments 114
• SWOT analysis 114

Chapter 11 Sanofi-Aventis (India) 116
• Summary 116
• Company overview 117
• Marketed products 117
• Therapeutic focus 118
• Research and development 119
• Growth strategies 119
• Leveraging parent company’s product portfolio 119
• Shifting focus to rural India 120
• Acquisitions and divestments 121
• SWOT analysis 122

Chapter 12 Mankind 124
• Summary 124
• Company overview 125
• Marketed products 126
• Therapeutic focus 126
• Research and development 127
• Growth strategies 128
• Expanding in international markets 128
• Investing in pharmaceutical capabilities development 128
• Foray into fast growing segments 128
• Acquisitions and divestments 129
• SWOT analysis 130

Chapter 13 11–20 companies 132
• Abbott (India) 132
• Company overview 132
• Marketed products 133
• Therapeutic focus 134
• Research and development 134
• Dr Reddy’s 135
• Company overview 135
• Marketed products 136
• Therapeutic focus 137
• Research and development 138
• Wockhardt 139
• Company overview 139
• Marketed products 140
• Therapeutic focus 140
• Research and development 141
• Aristo 142
• Company overview 142
• Marketed products 143
• Therapeutic focus 144
• Torrent Pharmaceuticals (Torrent) 145
• Company overview 145
• Marketed products 146
• Therapeutic focus 147
• Research and development 147
• Pfizer (India) 148
• Company overview 148
• Marketed products 149
• Therapeutic focus 150
• Research and development 151
• Intas 151
• Company overview 151
• Marketed products 152
• Therapeutic focus 152
• Research and development 153
• Alembic 154
• Company overview 154
• Marketed products 155
• Therapeutic focus 155
• Research and development 156
• FDC 157
• Company overview 157
• Marketed products 157
• Therapeutic focus 158
• Research and development 159
• Macleods Pharmaceuticals (Macleods) 160
• Company overview 160
• Marketed products 161
• Therapeutic focus 162
• Research and development 162
Chapter 14 Appendix 164
• Glossary 164
• Index 168

Browse complete Report at: http://www.reportsandreports.com/market-reports/the-top-10-pharmaceutical-companies-in-india-growth-strategies-/

Browse all Banking and Financial Services Market Research Reports at: http://www.reportsandreports.com/market-research/banking-services/

Browse all Datamonitor Market Research Reports at:
http://www.reportsandreports.com/Publishers/datamonitor/

Browse all Newly Published Market Research Reports at:
http://www.reportsandreports.com/LatestReport.aspx

Related Reports:

The Natural Gas Power Generation Technologies Market Outlook: Market overview, capacity, generation, new developments and the future outlook
http://www.reportsandreports.com/market-reports/the-natural-gas-power-generation-technologies-market-outlook-mar/

Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of legal, productivity, and quality control issues
http://www.reportsandreports.com/market-reports/strategies-for-managing-pharmaceutical-workforce-and-site-reducti/

The Western European Gas Market Outlook 2010: Country profiles of supply, demand, regulation and infrastructure
http://www.reportsandreports.com/market-reports/the-western-european-gas-market-outlook-2010-country-profiles-of/

About Reports and Reports
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites.

Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/